Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.
Professor Bertrand Tombal
Professor of Urology
Cliniques universitaires Saint-Luc & Université catholique de Louvain
Associate Professor Edmund Chiong
Head, Department of Urology
National University Hospital, Singapore